Actuate Therapeutics (ACTU) Stock Price, News, Quotes-Moomoo

Account Info

Log Out

US Stock MarketDetailed Quotes

ACTU Actuate Therapeutics

Watchlist

8.700
-0.260-2.90%

Trading Nov 19 09:59 ET

169.93MMarket Cap-5971P/E (TTM)

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment
WSJNov 12 08:34 ET
Express News | Actuate Therapeutics Inc - Topline Phase 1 Data for Elraglusib Expected in 2H 2025
ReutersNov 12 08:01 ET
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development
GlobeNewswireOct 29 18:39 ET
Actuate Therapeutics | 10-Q: Quarterly report
SECSep 24 16:07 ET · Announcements
Actuate Announces Scientific Reports Publication on Elraglusib's Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor
GlobeNewswireSep 23 08:00 ET
Actuate Announces Upcoming Presentation on Initial Data on Elraglusib in Combination With FOLFIRINOX at the AACR Special Conference on Advances in Pancreatic Cancer Research
GlobeNewswireSep 16 08:00 ET

Comments

Teddy123

Oct 29 22:55

Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development

$Actuate Therapeutics (ACTU.US)$
CHICAGO and FORT WORTH, Texas, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), announced that it will participate in “Webinar Wednesday” hosted b...